Efficacy of rivaroxaban versus vitamin K antagonists in preventing recurrent venous thromboembolism

Trial Profile

Efficacy of rivaroxaban versus vitamin K antagonists in preventing recurrent venous thromboembolism

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Oct 2015

At a glance

  • Drugs Rivaroxaban (Primary) ; Vitamin K antagonists
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Oct 2015 New trial record
    • 02 Sep 2015 Results presented at ESC Congress 2015: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top